FGFR4 Arg388基因型对新辅助化疗乳腺癌患者病理完全缓解的预测价值

doi:10.3969/j.issn.1671-7171.2021.09.032

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1148 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探究成纤维细胞生长因子受体4(FGFR4)基因Arg388单核苷酸多态性与新辅助化疗乳腺癌患者病理完全缓解(pCR)的相关性。【方法】选取浙江大学医学院附属儿童医院及附属第二医院行术前新辅助化疗的80例局部晚期乳腺癌患者,采集其化疗前外周静脉血,提取血DNA,采用聚合酶链反应(PCR)及限制性片段长度多态性(RFLP)检测FGFR4基因Arg388基因型,观察治疗后患者pCR情况,分析Arg388单核苷酸多态性与pCR的相关性。【结果】80例患者中,GG型15例,GA型25例,AA型40例,Arg388基因型与淋巴结转移具有相关性(P<0.05),GG型患者淋巴结转移率高于AA型,且差异有显著性(P<0.05)。共19例(23.75%)患者术后病理达pCR,Arg388 GG型患者pCR率低于AA型,且差异有显著性(P<0.05),GA型与AA型pCR率相比较差异无显著性(P>0.05)。单因素分析显示,TNM分期、分子分型、淋巴结状态是pCR的影响因素。Logistic分析显示TNM分期、分子分型、淋巴结状态、Arg388基因型均是pCR的独立影响因素(P<0.05)。【结论】FGFR4基因Arg388基因型与乳腺癌患者pCR相关,相比AA型患者,GG型患者淋巴结转移率高,pCR低,Arg388基因型对乳腺癌pCR具有一定预测作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：乳腺肿瘤/遗传学, 化学疗法,辅助, 基因型

Abstract：【Objective】To explore the correlation between Arg388 monocyte nucleotide polymorphism of fibroblast growth factor receptor 4 (FGFR4) gene and pathological complete remission (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.【Methods】A total of 80 patients with locally advanced breast cancer who received preoperative neoadjuvant chemotherapy in the children's Hospital Affiliated to Zhejiang University Medical College and its Second Affiliated Hospital of DNA were selected. Peripheral blood samples were collected before chemotherapy and blood was extracted. The FGFR4 gene Arg388 genotype was detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The pCR status of patients after treatment was observed. The relationship between Arg388 polymorphism and PCR was analyzed.【Results】There were 15 cases of GG genotype, 25 cases of GA genotype and 40 cases of AA genotype in 80 patients. Arg388 genotype was correlated with lymph node metastasis (P<0.05). The lymph node metastasis rate of patients with GG genotype was higher than that of patients with AA genotype, and the difference was significant (P<0.05). There were 19 cases (23.75%) with postoperative pathological PCR. The PCR rate of Arg388 GG type was lower than that of AA type (P<0.05), but there was no significant difference between GA type and AA type (P>0.05). Univariate analysis showed that TNM stage, molecular typing and lymph node status were the influencing factors of PCR. Logistic analysis showed that TNM stage, molecular typing, lymph node status and Arg388 genotype were independent influencing factors of PCR (P<0.05).【Conclusion】The Arg388 genotype of FGFR4 gene is associated with pCR in patients with breast cancer. Compared with patients with type AA, the rate of lymph node metastasis in GG patients is high and pCR is low. Arg388 genotype has a certain predictive effect on pCR of breast cancer.

Key words： Breast Neoplasms/GE Chemotherapy, Adjuvant Genotype

收稿日期: 2019-08-13

中图分类号:

R737.9

通讯作者: *E-mail:32850880@qq.com

引用本文:

曹琴, 胡晓玲, 徐志江, 彭朝阳, 叶义花. FGFR4 Arg388基因型对新辅助化疗乳腺癌患者病理完全缓解的预测价值[J]. 医学临床研究, 2021, 38(9): 1392-1395.
CAO Qin, HU Xiao-ling, XU Zhi-jiang, et al. Predictive Value of FGFR4 Arg388 Genotype for Pathological Complete Remission in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1392-1395.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.09.032 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I9/1392

[1] SPRING L, GREENUP R, NIEMIERKO A, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer[J].J Natl Compr Canc Netw,2017,15(10):1216-1223.
[2] CHEN Y, SHI X E, TIAN J H, et al. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis[J].Medicine (Baltimore),2018,97(20):e10634.
[3] AHMED M A, SELZER E, DORR W, et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer[J].Oncotarget,2016,7(43):69976-69990.
[4] WANG S, DING Z. Fibroblast growth factor receptors in breast cancer[J].Tumour Biol,2017,39(5):1393-1394.
[5] CHA Z, ZANG Y, GUO H, et al. Retraction Note to: Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma[J].Mol Biol Rep,2016,43(7):753.
[6] ANASTASIAGI Z, LIANOS G D, IGNATIADOU E, et al. Breast cancer in young women: an overview[J].Updates Surg,2017,69(3):313-317.
[7] LOIBL S, DENKERT C, VON MINCKWITZ G. Neoadjuvant treatment of breast cancer--Clinical and research perspective[J].Breast,2015,24 Suppl 2:S73-S77.
[8] CHENT H, YANG S F, LIU Y F, et al. Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis[J].Reprod Sci,2018,25(1):86-93.
[9] CHEN L, LEI Z, MA X, et al. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population[J].Sci Rep,2016,6(3):36-40.
[10] THUSSBAS C, NAHRIG J, STRIT S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer[J].J Clin Oncol,2006,24(23):3747-3755.
[11] MARME F, WERFT W, BENNER A, et al. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer[J].Ann Oncol,2010,21(8):1636-1642.
[12] TANG S, HAO Y, YUAN Y, et al. Role of fibroblast growth factor receptor 4 in cancer[J].Cancer Sci,2018,109(10):3024-3031.
[13] STADLER C R, KNYAZEV P, BANGE J, et al. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression[J].Cell Signal,2006,18(6):783-794.